<DOC>
	<DOCNO>NCT03091998</DOCNO>
	<brief_summary>The worldwide use leave ventricular assist device ( LVAD ) , mechanical device improve hemodynamic function , improve outcome severe heart failure ( HF ) patient lead continued annual increase number LVAD implantation . However LVAD support still result major complication renal failure gastrointestinal bleeding . The investigator hypothesize major complication may due endothelial dysfunction induce lack pulsatility , may improve innovative designer natriuretic peptide , CD-NP . They demonstrate favorable action animal model well human , test safety LVAD patient . They hypothesize CD-NP renal endothelial protective action receptor GC-A GC-B . Thus , investigator test hypothesis highly translational approach examine CD-NP 's role endothelial renal protection . The aim determine safety tolerability together cGMP activating , neurohumoral modulate renovascular protective property chronic subcutaneous delivery CD-NP compare placebo stable LVAD patient 3 day .</brief_summary>
	<brief_title>Subcu Administration CD-NP Heart Failure Patients With Left Ventricular Assist Device Support</brief_title>
	<detailed_description>Stable patient LVAD implantation ( 3 month s/p implantation ) undergo 3-day test Mayo Clinic 's Clinical Research Trials Unit . They undergo daily subcutaneous injection CD-NP , placebo , 3 day hemodynamic monitoring , ECHO , endothelial function assessment , renal blood flow monitoring . Blood urine sample also collect assayed .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Male nonpregnant/postmenopausal/sterile female , age 1890 , endstage HF LVAD support stable heal stage least 3 month LVAD implant ( Destination therapy ) ( postmenopausal state define absence menses ≥ 1 year serum folliclestimulating hormone ≥ 20 IU/L ; sterilization female define bilateral tubal occlusion ≥ 6 month , bilateral oophorectomy , complete hysterectomy ) Be willing provide inform consent . All cardiac medication must stable dos 4 week prior enrollment . Known allergy adverse reaction exogenous natriuretic peptide ( CDNP component , nesiritide , natriuretic peptide , related compound ) . Women pregnant , breastfeed . Having receive nesiritide within 7 day prior entry study . Having receive investigational drug device within 30 day prior entry study . Clinically unstable patient ( e.g . mean blood pressure &lt; 70 mmHg , ongoing requirement vasopressor , mechanical ventilation ) . Recent hospitalization decompensated HF recent defibrillation cardiac resuscitation within 30 day prior randomization . Patients guard prognosis unlikely derive meaningful benefit CDNP . Presence cardiac lesion comorbidities may contraindicate use natriuretic peptide , clinically significant cardiac valvular stenosis , hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , uncorrected congenital heart disease contraindicates use vasodilator . Symptomatic carotid artery disease , know critical carotid stenosis , stroke within past 3 month Requirement pressor maintenance blood pressure . Intraaortic blood pump use . Severe aortic mitral stenosis significant LV outflow tract obstruction . Clinically significant renal artery stenosis &gt; 50 % Baseline hemoglobin &lt; 9.0 g/dl . Serum sodium &lt; 130 mEq/L , potassium &lt; 3.6 mEq/L , magnesium &lt; 1.5 mEq/L . Elevated aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) least 5 time upper limit normal bilirubin least 5 time upper limit normal Creatinine clearance ( CrCl ) &lt; 30 ml.min1.1.73m2 , calculate CockcroftGault formula ( 67 ) adjust body surface area within 3 month requirement dialysis . Written history alcohol drug abuse within past 6 month . Inability communicate effectively study personnel . BMI &gt; 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>